Anti-Rb RB1 Rabbit Monoclonal Antibody

All lanes use the Antibody at 1:3K dilution for 1 hour at room temperature.

Western blot analysis of Rb using anti-Rb antibody (M00039-2).
Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours. The sample well of each lane was loaded with 30 ug of sample under reducing conditions.
Lane 1: human Jurkat whole cell lysates,
Lane 2: human MCF-7 whole cell lysates,
Lane 3: human 293T whole cell lysates,
Lane 4: human K562 whole cell lysates.
After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-Rb antigen affinity purified monoclonal antibody (M00039-2) at 1:1000 overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:500 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for Rb at approximately 106 kDa. The expected band size for Rb is at 106 kDa.

Changes in chromatin accessibility are consistent with global transcriptome changes. A. Genome tracks showing a comparison of ATAC-seq profiles of RB1 in apatinib-resistant and non-resistant HepG2 cells. B. The mRNA expression levels of RB1 in apatinib-resistant versus untreated HepG2 cells, statistical analysis was performed by Student t-test. C. Boxplots of chromatin accessibility values for high expression genes and low expression genes in apatinib-resistant cells.
Index in PubMed under a CC BY license. PMID: 37781033

Expression status of RB1 pathway targets in HCC cells and in clinical samples; CDK2-IN-73 and Palbociclib can relieve apatinib resistance. A. qPCR analysis showed that the expression levels of RB1, PCNA, KIAA0101 and MCM7 in HepG2-resistant cells were significantly reduced, and the expression levels of CDKN2B andCDKN2AIP were increased. B. Western blot detection of the above proteins is consistent with qPCR detection results. C. Analysis of mRNA expression of five PD patients showed high expression of CDKN2B and low expression of RB1, PCNA, and MCM7. D. Western blot analysis showed that PD patients had high expression of CDKN2B but low expression of RB1, PCNA, and MCM7. E. Representative photographs of staining of RB1 protein in a pair of HCC patients tissues in PD and PR (20X). F. Representative photographs of staining of CDKN2B protein in a pair of HCC patients tissues in PD and PR (20X). G. The proliferation inhibition curves of resistant HepG2 cells and HepG2 cells treated with CDK2-IN-73. H. Western blot analysis showed that the expression of CDKN2B in HepG2resistant cells was not significantly different, and the expression levels of RB1, PCNA and MCM7 were upregulated. I. Proliferation inhibition curves of HepG2 resistant cells and HepG2 cells treated with Palbociclib. J. Western blot analysis results showed that the expression levels of RB1, PCNA, and MCM7 were upregulated. The bars represent mean ± standard deviation; ∗ P < 0.05.
Index in PubMed under a CC BY license. PMID: 37781033

Immunohistochemical analysis of paraffin-embedded Rat lung, using the Antibody at 1:250 dilution.

Immunohistochemical analysis of paraffin-embedded Human tongue cancer, using the Antibody at 1:250 dilution.

Immunohistochemical analysis of paraffin-embedded Human renal cancer, using the Antibody at 1:250 dilution.

Immunohistochemical analysis of paraffin-embedded Human kidney, using the Antibody at 1:1000 dilution.

Immunohistochemical analysis of paraffin-embedded Mouse spleen, using the Antibody at 1:250 dilution.

Immunohistochemical analysis of paraffin-embedded human lung cancer, using Retinoblastoma Antibody.

Immunofluorescent analysis using the Antibody at 1:50 dilution.

Immunofluorescent analysis of SH-SY5Y cells, using Retinoblastoma Antibody.